Who Paid My Doc
Sean Barlow
Addiction Psychiatry Palm Desert, CA Medical Doctor
NPI 1386653178 CMS profile 243910
41990 Cook St, Building F Suite 2008, Palm Desert, CA 92211
General payments
$3,853
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Sean Barlow of Palm Desert, CA is reported in the CMS Open Payments database as having received $3,853 across 153 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 87th percentile of Addiction Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $444 | 17 | |
| 2024 | General | $458 | 39 | |
| 2023 | General | $472 | 15 | |
| 2022 | General | $1,150 | 51 | |
| 2021 | General | $1,120 | 26 | |
| 2019 | General | $208 | 5 |
Beside peers
- Sean Barlow
- Addiction Psychiatry median
- Middle half of Addiction Psychiatry
- National median
In program year 2025, general payments to Sean Barlow were reported at $444. Among 180 Addiction Psychiatry profiles paid that year, the median was $138 and the middle half received between $45 and $421.
Show as a table
| Year | Sean Barlow | Addiction Psychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $208 | $142 | $56–$476 | $163 |
| 2020 | $0 | $78 | $21–$210 | $114 |
| 2021 | $1,120 | $112 | $35–$458 | $132 |
| 2022 | $1,150 | $113 | $39–$343 | $149 |
| 2023 | $472 | $134 | $47–$429 | $160 |
| 2024 | $458 | $129 | $42–$349 | $164 |
| 2025 | $444 | $138 | $45–$421 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 41 drugsPart D claims
1,164
Drug cost
$98,310
Branded share of claims
15.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Caplyta Lumateperone Tosylate | Brand | 12 | $19,574 | |
| Vraylar Cariprazine Hcl | Brand | 12 | $16,609 | |
| Chlorpromazine Hcl | Generic | 15 | $10,417 | |
| Fluvoxamine Maleate Er Fluvoxamine Maleate | Brand | 14 | $8,132 | |
| Belsomra Suvorexant | Brand | 20 | $7,102 | |
| Asenapine Maleate | Generic | 26 | $5,890 | |
| Dayvigo Lemborexant | Brand | 12 | $3,859 | |
| Paliperidone Er Paliperidone | Brand | 12 | $2,998 | |
| Quetiapine Fumarate | Generic | 94 | $2,580 | |
| Ziprasidone Hcl | Generic | 20 | $2,481 |
The 10 drugs with the highest cost, of 41 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 7 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| VRAYLAR |
|
$186 | 12 | — |
| ARISTADA |
|
$91 | — | — |
| CAPLYTA |
|
$70 | 12 | — |
| Auvelity |
|
$30 | — | — |
| INVEGA SUSTENNA |
|
$26 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 7 in the dashboard with a free accountRecords
153 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Addiction Psychiatry in California
Robert Anthenelli
Addiction Psychiatry · San Diego, CA
Ariel Gavino
Addiction Psychiatry · Anaheim, CA
Edward Moore
Addiction Psychiatry · Beverly Hills, CA
Frank Tan
Addiction Psychiatry · Los Angeles, CA
Juan Pequeno
Addiction Psychiatry · Needles, CA
Muhammad Iqbal
Addiction Psychiatry · North Hills, CA
Related records
Addiction Psychiatry in California
Practitioners in the same specialty and state, ranked by reported value.
All Addiction Psychiatry
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.